Search the Site

Twitter

test tubes

Run-Up Analysis: ALXA, AVNR, and BIOD

publication date: Oct 25, 2010
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
As October begins to wind down, we can step back and take a look at three of the key run-up plays this month.  These are ALXA (10/11), AVNR (10/30), and BIOD (10/30).  The early sell-offs in these stocks were significant and my represent a necessary shift in the 'Run-Up" method.  Lets take a look and how these plays panned out, and see what changes we can make to capitalize on the upcoming FDA decisions throughout the remainder of 2010.


Sorry this page is available to subscribers only. If you're not a subscriber why not join today?

You can also sign up for our 100% FREE Newsletter  to stay current on public webinars, special offers, and news alerts:

FREE NEWSLETTER

If you are already a subscriber, please login.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site including:

- Detailed Reports on Upcoming FDA and Clinical Trial Trades
- REAL TIME Posting of Trades (Entries and Exits)
- Clinical and Regualtory Catalyst Database with over 300 events and updated daily 
- Members Only Live Interactive Webinars 
- Weekly Watchlist
- Email / SMS (Text Message) Alerts of critical news
- Access to view Mark Messier and Mike Havrilla's Trading Accounts
- A More Detailed FDA Calendar
- Direct Email Communication
- Affiliate Program

If you believe you should be able to view this area then please contact us and we will try to rectify this issue as soon as possible.